D&D Pharmatech, Inc. announced it has entered into a sponsored research agreement with Yale University relating to optimization of two novel approaches that allow immune system cells and drug molecules to bypass the blood-brain barrier for the treatment of brain cancer and other disorders.
[D&D Pharmatech, Inc. (Business Wire, Inc.))]
6445212
{6445212:nan}
apa
50
1
161564
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
